Avadel Pharmaceuticals PLC Sponsored ADR Stock

$10.90

1.18% today

Nasdaq, Jul 28, 05:46 pm CET

ISIN

US05337M1045

Symbol

AVDL

Reports

Quarter | Annual

Index

NASDAQ Composite

Sector

Pharmaceuticals, Biotechnology & Life Sciences

Industry

Pharmaceuticals

Overview Dividends Analysts Charts News Strategies

Avadel Pharmaceuticals PLC Sponsored ADR Stock price

$11.03

+2.78 33.70% 5Y

Nasdaq, Closing price Fri, Jul 25 2025

-0.22 1.96%

ISIN

US05337M1045

Symbol

AVDL

Reports

Quarter | Annual

Index

NASDAQ Composite

Sector

Pharmaceuticals, Biotechnology & Life Sciences

Industry

Pharmaceuticals

Key metrics

Basic

Market capitalization

$1.1b

Enterprise Value

$1.0b

Net debt

positive

Cash

$66.5m

Shares outstanding

96.6m

Valuation (TTM | estimate)

P/E

negative | 48.2

P/S

5.5 | 4.0

EV/Sales

5.2 | 3.8

EV/FCF

negative

P/B

14.4

Financial Health

Equity Ratio

45.0%

Return on Equity

-66.1%

ROCE

-16.6%

ROIC

-20.8%

Debt/Equity

0.0

Financials (TTM | estimate)

Revenue

$194.5m | $265.3m

EBITDA

$-16.4m | $37.0m

EBIT

$-19.4m | $28.6m

Net Income

$-26.4m | $22.1m

Free Cash Flow

$-25.4m

Growth (TTM | estimate)

Revenue

252.7% | 56.9%

EBITDA

88.8% | 193.2%

EBIT

87.0% | 167.5%

Net Income

83.2% | 145.3%

Free Cash Flow

80.1%

EPS

$-0.3

FCF per Share

$-0.3

Short interest

14.8%

Employees

188

Rev per Employee

$900.0k

As a Free StocksGuide user, you can view scores for all 7,028 stocks worldwide.

Get Started for Free Today

Avadel Pharmaceuticals PLC Sponsored ADR Stock Analysis

Unlock Scores for Free

??

15 Analysts have issued a Avadel Pharmaceuticals PLC Sponsored ADR forecast:

14x Buy

93%

More details on Analyst Estimates Including Price Targets

15 Analysts have issued a Avadel Pharmaceuticals PLC Sponsored ADR forecast:

Buy

93%

Hold

Analyst Estimates with Stock Price Targets

Financial data from Avadel Pharmaceuticals PLC Sponsored ADR

Income Statement P&L | Balance Sheet | Cash Flow

Quarter TTM Annually

Mar '25		+/- %
Revenue	194 194	253% 253% 100%
- Direct Costs	19 19	716% 716% 10%
Gross Profit	175 175	232% 232% 90%
- Selling and Administrative Expenses	178 178	1% 1% 92%
- Research and Development Expense	16 16	32% 32% 8%
EBITDA	-16 -16	89% 89% -8%
- Depreciation and Amortization	2.97 2.97	73% 73% 2%
EBIT (Operating Income) EBIT	-19 -19	87% 87% -10%
Net Profit	-26 -26	83% 83% -14%

In millions USD.

If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.

Subscribe Now

Avadel Pharmaceuticals PLC Sponsored ADR Stock News

Neutral

GlobeNewsWire

●

7 days ago

Avadel Announces Grant of Inducement Awards Under Nasdaq Listing Rule 5635(c)(4)

DUBLIN, July 21, 2025 (GLOBE NEWSWIRE) -- Avadel Pharmaceuticals plc (Nasdaq: AVDL), a company focused on transforming medicines to transform lives, today announced that the Compensation Committee of Avadel's Board of Directors approved the grant of non-statutory options to six (6) new employees to purchase 34,200 ordinary shares under Avadel's 2021 Inducement Plan. The awards were granted as a...

Neutral

Business Wire

●

14 days ago

ASL Strategic Value Fund Issues Open Letter to Avadel Shareholders

GREENWICH, Conn. & CHESTERFIELD, Mo.--(BUSINESS WIRE)--ASL Strategic Value Fund, LP (together with its affiliates, “ASL Strategic Value Fund” or “we”), a significant shareholder of Avadel Pharmaceuticals plc (NASDAQ: AVDL) (“Avadel” or the “Company”), today issued an open letter calling on Avadel's shareholders to vote AGAINST all of the Company's director nominees up for election at the 2025 a...

Negative

Reuters

●

28 days ago

ASL pushes for board shakeup at Avadel over handling of sleep drug rollout

ASL Strategic Value Fund on Monday urged shareholders of Avadel Pharmaceuticals to replace its board, citing mismanagement in the rollout of the drugmaker's flagship sleep disorder drug Lumryz since its launch two years ago.

More Avadel Pharmaceuticals PLC Sponsored ADR News

Company Profile

Avadel Pharmaceuticals Plc engages in the development and commercialization of pharmaceutical products. It offers Bloxiverz, Vazculep, and Akovaz. The company was founded on December 1, 2015 and is headquartered in Dublin, Ireland.

Head office	Ireland
CEO	Gregory Divis
Employees	188
Founded	2015
Website	www.avadel.com

Register for Free

StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.

Start now